


# Koios Medical, Inc.

Financial Statements and Report

December 31, 2025

## Table of Contents

Independent Auditor's Report . . . . .	2
Balance Sheet . . . . .	5
Statement of Income . . . . .	8
Statement of Changes in Stockholders' Equity . . . . .	9
Statement of Cash Flows . . . . .	10
Notes to the Financial Statements . . . . .	12



# TESSERACT ADVISORY GROUP

## Independent Auditor's Report

To Management of:  
Koios Medical, Inc.

### **Report on the Audit of the Financial Statements**

#### ***Opinion***

We have audited the financial statements of Koios Medical, Inc., which comprise the balance sheet as of December 31, 2025, and the related statement of income, statement of changes in stockholders' equity, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Koios Medical, Inc. as of December 31, 2025, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

#### ***Basis for Opinion***

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Koios Medical, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## ***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Koios Medical, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

## ***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Koios Medical, Inc., Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Koios Medical, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters

that we identified during the audit.

***Substantial Doubt About the Company's Ability to Continue as a Going Concern***

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 12 to the financial statements, the Company has had recurring losses from operations and consistent net cash outflows from operations and management has stated that substantial doubt exists about the Company's ability to continue funding operations. These conditions raise an uncertainty about the Company's ability to continue as a going concern for the year following the issuance of these financial statements. Management's evaluation of these conditions and management's plans regarding these matters are also described in Note 12. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. Our conclusion is not modified with respect to this matter.

*Tesseract Advisory Group LLC*

---

Tesseract Advisory Group, LLC  
OWINGS MILLS, MD  
April 9, 2026

**Koios Medical, Inc.**  
Balance Sheet  
As of December 31, 2025

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
**Balance Sheet**  
As of December 31, 2025

<b>Assets</b>	
<b>Current Assets</b>	
Cash and cash equivalents	\$ 168,058
Accounts receivable, net of allowance for doubtful accounts	322,821
Related party receivables	33,004
Prepaid expenses	95,974
<b>Total Current Assets</b>	<b>619,857</b>
<b>Noncurrent Assets</b>	
Property, plant, and equipment, net	12,956
Right-of-use assets, operating leases	114,692
Security deposits	5,908
<b>Total Noncurrent Assets</b>	<b>133,556</b>
<b>Total Assets</b>	<b>753,413</b>
<b>Liabilities &amp; Stockholders' Equity</b>	
<b>Liabilities</b>	
<b>Current Liabilities</b>	
Accounts payable and accrued expenses	943,577
Operating lease liabilities, current	114,692
Deferred revenue, current	708,149
<b>Total Current Liabilities</b>	<b>1,766,418</b>
<b>Noncurrent Liabilities</b>	
Debt, noncurrent	600,000
Deferred revenue, noncurrent	388,702
<b>Total Noncurrent Liabilities</b>	<b>988,702</b>
<b>Total Liabilities</b>	<b>2,755,120</b>
<b>Stockholders' Equity</b>	
Series A voting preferred stock \$0.00001 par value, 6,333,209 shares authorized; 6,333,209 shares issued and outstanding	63
Series B voting preferred stock \$0.00001 par value, 5,650,000 shares authorized; 4,755,193 shares issued and outstanding	48
Series C voting preferred stock \$0.00001 par value, 6,333,209 shares authorized; 536,708 shares issued and outstanding	5
Common stock, \$0.00001 par value, 22,000,000 shares authorized; 6,705,324 shares issued and 4,433,774 outstanding	67
Treasury stock at cost (2,271,550 shares of common stock)	(2,271,550)
Additional paid-in capital	41,864,876
Accumulated Deficit	(41,595,216)
<b>Total Stockholders' Equity</b>	<b>(2,001,707)</b>

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Balance Sheet  
As of December 31, 2025

---

<b>Total Liabilities &amp; Stockholders' Equity</b>	\$	753,413
---	----	---------

---

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Statement of Income  
For the year ended December 31, 2025

Revenues	\$ 1,620,593
Cost of sales	293,128
<b>Gross Profit</b>	<b>1,327,465</b>
<b>Operating Expenses</b>	
Selling expenses	866,026
General and administrative expenses (includes noncash compensation of \$45,623)	1,775,075
Research and development	1,250,892
<b>Total Operating Expenses</b>	<b>3,891,993</b>
<b>Operating Income (Loss)</b>	<b>(2,564,528)</b>
<b>Other Income (Expense)</b>	
Interest expense	(122,700)
<b>Net Income (Loss)</b>	<b>\$ (2,687,228)</b>

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Statement of Changes in Stockholders' Equity  
For the year ended December 31, 2025

	Series A Preferred Shares	Series AB Preferred A	Series Preferred SharesB	Series Preferred Shares	Series C Preferred Stock	Series C Preferred Amount	Common Stock Shares	Common Stock Amount	Additional Paid-In Capital	Treasury Stock	Accumulate Deficit	Total Stockholde Equity
Balance at December 31, 2024	6,333,209	\$ 63	4,736,494	\$ 47	-	\$	6,673,512	\$ 67	39,580,718	(2,271,550)	38,907,988	(1,598,643)
Net income (loss)	-	-	-	-	-	-	-	-	-	-	(2,687,228)	(2,687,228)
Issuance of Preferred B Shares	-	-	18,699	1	-	-	-	-	74,999	-	-	75,000
Issuance of Preferred C Shares	-	-	-	-	536,708	5	-	-	2,155,191	-	-	2,155,196
Issuance of common stock	-	-	-	-	-	-	31,812	-	8,345	-	-	8,345
Stock-based compensation	-	-	-	-	-	-	-	-	45,623	-	-	45,623
<b>Balance at December 31, 2025</b>	<b>6,333,209</b>	<b>\$ 63</b>	<b>4,755,193</b>	<b>\$ 48</b>	<b>536,708</b>	<b>\$ 5</b>	<b>6,705,324</b>	<b>\$ 67</b>	<b>41,864,876</b>	<b>(2,271,550)</b>	<b>41,595,216</b>	<b>(2,001,707)</b>

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Statement of Cash Flows  
For the year ended December 31, 2025

**Cash Flows**

<b>Cash Flows From Operating Activities</b>	
Net income (loss)	\$ (2,687,228)
<b>Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities</b>	
Depreciation	10,482
Change in allowance for bad debts	13,256
Amortization of right-of-use assets	94,522
Share based compensation - options	45,623
<b>Total Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities</b>	<b>163,883</b>
<b>(Increase) decrease in operating assets, net of effects of businesses acquired</b>	
Accounts receivable	(224,514)
Related party receivables	(3,514)
Prepaid expenses	(5,536)
Security deposits	49,809
<b>Increase (decrease) in operating liabilities, net of effects of businesses acquired</b>	
Accounts payable and accrued liabilities	61,381
Operating lease obligations	(94,522)
Deferred revenue	602,000
<b>Net Cash Provided by (Used in) Operating Activities</b>	<b>(2,138,241)</b>
<b>Cash Flows from Investing Activities</b>	
Purchase of property, plant, and equipment	(8,668)
<b>Cash Flows from Financing Activities</b>	
Proceeds from issuance of debt	320,000
Repayment of debt	(290,000)
Proceeds from Issuance of Preferred B-3 stock, net of issuance costs	75,000
Proceeds from issuance of Preferred CF-1 and CF-2 stock, net of issuance costs	2,155,197
Proceeds from issuance of common stock	8,345
<b>Net Cash Provided by (Used in) Financing Activities</b>	<b>2,268,542</b>
<b>Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash</b>	<b>121,633</b>
Cash, cash equivalents, and restricted cash at beginning of year	46,425
<b>Cash, Cash Equivalents, and Restricted Cash at End of Year</b>	<b>168,058</b>

**Supplemental Cash Flow Information**

**Cash Paid During the Year for**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Statement of Cash Flows  
For the year ended December 31, 2025

Interest	\$ 90,682
----------	-----------

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

## **Notes to the Financial Statements**

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

**1. Summary of significant accounting policies**

**a. Nature of operations**

Koios Medical, Inc. (the Company) was incorporated in the state of Delaware on April 6, 2011 as "Clearview Diagnostics, Inc." and amended and restated the Certificate of Incorporation on April 26, 2018 to change the name to Koios Medical, Inc. The Company is a privately held medical technology company specializing in the application of artificial intelligence learning to diagnostic radiology.

The Company's breast and thyroid ultrasound image analysis and decision software is a registered device with the FDA and is protected by fifteen US and international patents and several pending patents related to image processing and machine learning for radiology.

**b. Basis of accounting**

The Company's financial statements have been prepared using the accrual basis of accounting in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") of the Financial Accounting Standards Board ("FASB").

**c. Use of estimates**

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.

**d. Fair value measurements**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company determines fair value measurements used in its financial statements based upon the exit price, that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive for any transaction costs. A fair value hierarchy provides for prioritizing inputs to valuation techniques used to measure fair value into three levels:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.

Level 3 - Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.

An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company's cash, current assets and liabilities are carried at cost, which approximates fair value due to the short-term nature of these instruments.

**e. Income taxes**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic 740, *Income Taxes*. Under the asset and liability method, deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company also accounts for uncertain tax positions in accordance with ASC Topic 740, *Income Taxes*. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company's income tax returns. As of December 31, 2025, the Company had no uncertain tax positions which affected its financial position, its results of operations or its cash flows, and will continue to evaluate for uncertain tax positions in the future. There are no estimated interest costs or penalties provided for in the Company's financial statements for the years ended December 31, 2025. If at any time the Company should record interest and penalties in connection with income taxes, the interest and the penalties will be expensed within the interest and general and administrative expenses.

**f. Cash and cash equivalents**

Cash and cash equivalents includes short-term investments and highly liquid investments in money market instruments which are carried at the lower of cost and market value with a maturity date of three months or less from the acquisition date. These are valued at cost which approximates market value.

**g. Accounts receivable**

Accounts receivable are reported at their outstanding unpaid balance reduced by an allowance for doubtful accounts. The Company estimates allowance for doubtful accounts based on historical experience and management's evaluation of outstanding receivables. Accounts are written off when they are deemed uncollectible. As of December 31, 2025, the Company has an allowance for doubtful accounts of \$16,250.

**h. Property, plant and equipment**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Property, plant and equipment is recorded at cost. Expenditures for additions, improvements and other enhancements to property, plant and equipment are capitalized, and minor replacements, maintenance, and repairs that do not extend asset life or add value are charged to expense as incurred. When property, plant and equipment assets are retired or otherwise disposed of, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in results of operations for the respective period. Exchange of nonmonetary assets that have commercial substance are measured based on the fair value of the assets exchanged.

In general, depreciation is the systematic and rational allocation of an asset's cost, less its residual value (if any), to the periods it benefits. The Company's property, plant and equipment is depreciated using the straight-line method, which results in depreciation expense being incurred evenly over the life of an asset. Estimates of depreciation expense incorporates management assumptions regarding the useful economic lives and residual values of the Company's assets. The Company periodically reviews and adjusts, as appropriate, the residual values and useful lives of its assets.

Property recorded as furniture is depreciated over 5 years. Expenditures for repairs and maintenance are expensed as incurred.

**i. Leases**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

In February 2016, the FASB issued guidance ASC Topic 842, Leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use ("ROU") assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.

The Company adopted the standard effective January 1, 2022 and recognized and measured leases existing at January 1, 2022 (the beginning of the period of adoption), with certain practical expedients available. Lease disclosures for the year ended December 31, 2021 are made under prior lease guidance in FASB ASC 840. Accordingly, the Company applied the guidance to each lease that had commenced as of the adoption date and also elected a package of practical expedients which included the following: no requirement to reassess the following:

- (a) whether any expired or existing contracts are, or contain, leases,
- (b) the lease classification for any expired or existing leases, and
- (c) the recognition requirements for initial direct costs for any existing leases.

The Company also elected a practical expedient to account for lease and non-lease components as a single lease component for all classes of underlying assets.

The Company excludes short-term leases having initial terms of twelve months or less from the new guidance as an accounting policy election and recognizes rent expense for such leases on a straight-line basis over the lease term. In calculating the related lease liabilities at the time of adoption, the Company utilized historical experience when determining the noncancelable portion of the lease term and elected to use the risk-free rate as the discount rate. The Company determines if an arrangement is a lease at inception.

The Company leases its building facility and records the lease as operating lease ROU assets and operating lease liabilities (current portion and long-term portion) on the accompanying consolidated balance sheet. Operating lease ROU assets and the related lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease ROU assets also include lease incentives and initial direct costs incurred. For operating leases, interest on the lease liability and the amortization of ROU asset result in straight-line rent expense over the lease term.

**j. Revenue recognition**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

ASC Topic 606, "Revenue from Contracts with Customers" establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity's contracts to provide goods or services to customers. Revenues are recognized when control of the promised goods or services is transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: 1) identify the contract with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to performance obligations in the contract; and 5) recognize revenue as the performance obligation is satisfied.

Software access and support revenue is recognized over the term of the contract. Installation revenue is recognized when the service is performed.

**k. Cost of sales**

Costs of sales includes expenses directly related to the deployment of Koios DS software. These expenses include salaries, related payroll expenses, and travel and meals for employees associated with software deployment and enablement and engagement related to the training of end users of Koios DS software.

**l. Deferred revenue**

Deferred revenue is a liability primarily related to billings in advance of revenue recognition from the Company's software access and support revenue described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in annual installments. Amounts that have been invoiced are initially recorded in accounts receivable and deferred revenue. Deferred revenue that will be recognized in the succeeding 12-month period is recorded in other current liabilities on the balance sheet.

**m. Research and development expenses**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct software image analysis testing and manufacture diagnostic supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.

**n. Stock-based compensation**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company recognizes expense for stock-based compensation in accordance with ASC Topic 718, *Stock- Based Compensation*. ASC 718 addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for equity instruments of the enterprise or liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires the Company measures all stock options and other stock-based awards granted to employees based on the fair value on the date of the grant and recognizes compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award, and is calculated using the Black-Scholes option-pricing model. Generally, the Company issues stock options to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method.

In consideration the fair value of the underlying stock when the Company granted options, the Company will consider several factors including the fair values established by market transactions. Stock option-based compensation includes significant estimates and judgments of when stock options might be exercised, forfeiture rates and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period the estimates are revised.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical data regarding the volatility of a publicly traded set of peer companies. The expected term of stock options granted to nonemployees is between 5 and 7 years. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.

**o. Long-term debt**

Non-interest-bearing debt is carried at its amortized cost using the effective interest rate method.

**p. Comprehensive income**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company does not have any comprehensive income items other than net income.

**2. Related party transactions**

The Customer Group is an entity managed and controlled by Koios Medical CEO, Chad McClennan. The Customer Group is not currently an active consulting operation. The Customer Group continues to use an American Express account. For convenience, Koios Medical has agreed to pay The Customer Group American Express account used by Koios Medical CEO Chad McClennan. The vast majority of any amounts charged to this American Express card are for expenses that are for Koios Medical. A few expenses on this American Express card are the responsibility respectively of The Customer Group or Chad McClennan personally. Koios Medical finance personnel review all expenses on this American Express card monthly and allocate the expenses to the appropriate party. Both The Customer Group and Chad McClennan have agreed to repay amounts advanced by Koios Medical and paid to America Express on their behalf. Koios Medical does not charge interest on outstanding amounts owed and there is at present no definitive date set for repayment.

For the year ended December 31, 2025, the total amount of general and administrative expenses recognized under these arrangements was \$3,514. The cumulative balance owed to the Company under these arrangements was \$33,004 as of December 31, 2025.

**3. Prepaid expenses**

Prepaid expenses consist of the following:

Prepaid insurance	\$	20,059
Other prepaid expenses		75,915
<b>Total</b>	<b>\$</b>	<b>95,974</b>

**4. Property, plant, and equipment**

The historical costs of the Company's property, plant and equipment and related accumulated depreciation balances are as follows:

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Furniture and equipment	\$ 211,565
Total Accumulated Depreciation	(198,609)
<b>Property, plant, and equipment, net</b>	<b>\$ 12,956</b>

Depreciation expense during the year ended December 31, 2025 was \$10,482, which is included in general and administrative expenses.

### 5. Operating leases

The Company leases office space in 242 West 38th Street, New York, NY United States under operating lease agreements. The Company extended its lease until March 2027 to reduce the monthly lease payments. As this modification does not result in recognition of separate contract, the Company reallocated the remaining consideration in the contract and remeasured the lease liability using a discount rate for the lease determined at the effective date of the extension. The Company also reassessed the lease classification and concluded it to be an operating lease. As a result of the lease extension, the Company remeasured its lease liability and recognized the amount resulting from the re-measurement of the lease liability as an adjustment to the corresponding ROU Asset.

The monthly rent is \$8,209 plus sprinkler, water and sewer fees of \$170. The Company is also required to pay utilities, insurance and other costs relating to the leased facilities which are variable. The lease was granted for fixed rental payments with no rent holidays or any lease incentives during the lease renewal term and also does not contain any bargain purchase options or any extended renewal options.

Rent expense for the year ended December 31, 2025 was approximately \$85,875 which included operating lease expenses associated with the lease. The Company's lease liabilities all mature as of March 31, 2027.

The following inputs are included in the measurement of operating lease liabilities:

Weighted-average remaining lease term	15 months
Weighted-average discount rate	14%

### 6. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following:

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Trade accounts payable	\$ 624,738
Accrued expenses	78,566
Accrued payroll and related benefits	187,174
Interest payable	52,611
Sales and excise tax payable	488
<b>Total</b>	<b>\$ 943,577</b>

**7. Income taxes**

At December 31, 2025, deferred taxes are as follows:

Net operating loss carryforwards	\$ 10,853,309
Capitalized research and development costs	969,516
Stock based compensation	43,801
Research credit carryforward	835,899
Charitable contributions	7,024
Other deferred items	3,627
<b>Total</b>	<b>12,713,176</b>
Valuation Allowance	\$ (12,713,176)
<b>Net deferred tax assets</b>	<b>-</b>

The Company does not have a current tax provision in 2025 due to net losses generated for income tax purposes. As the Company is unable to conclude, due to its pre-tax losses since inception, that it is more likely than not that the benefits will be realized, it has provided a valuation allowance to offset the related deferred tax assets. The valuation allowance increased by \$2,859,684 during the year ended December 31, 2025.

Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company's net operating loss carryforwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance.

**8.**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

**Promissory notes**

During 2025, the Company had the following outstanding Promissory Notes:

Note to shareholder: \$100,000 principal; 18% interest, principal and accrued interest due December 31, 2027	\$ 100,000
Note to shareholder: \$425,000 principal; 18% interest, principal and accrued interest due December 31, 2027	425,000
Note to shareholder: \$75,000 principal; 18% interest, principal and accrued interest due December 31, 2027	75,000
<b>Total Promissory Note Principal</b>	<b>\$ 600,000</b>

During the year ended December 31, 2025, the Company incurred interest expense of \$122,700, of which \$52,611 was accrued.

Future principal repayments on long-term debt are as follows:

2026	-
2027	\$ 600,000
<b>Total</b>	<b>\$ 600,000</b>

**9. Stockholders' equity**

**a. Overview**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company's certificate of incorporation, as amended by the Fourth Amended and Restated Certificate of Incorporation on December 1, 2025, authorized the issuance of two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock". The Company's capital structure consists of Common Stock and Preferred Stock with certain rights and privileges summarized below. Preferred Stock is further subdivided into classes as indicated below. The total number of shares of capital stock that the Company has available to issue is 35,750,856 consisting of 22,000,000 shares of Common Stock, par value \$0.00001 per share and 13,750,856 shares of Preferred Stock, par value \$0.00001 per share with Preferred Stock designated as follows: 6,333,209 shares of Series A Preferred Stock, 1,200,000 shares of Series B-1 Preferred Stock, 1,200,000 shares of Series B-2 Preferred Stock, 3,250,000 shares of Series B-3 Preferred Stock, 650,000 shares of Series CF-1 Preferred Stock, 117,647 shares of Series CF-2 Preferred Stock, and 1,000,000 shares of Series CF-3 Preferred Stock.

**b. Series A, B, and CF Preferred Stock:**

The Series A, B, and CF Preferred Stock have the following summarized terms:

**i. Dividends**

The Series A, Series B and Series CF Preferred Stock do not have a stated dividend rate. The Company cannot declare, pay or set aside any dividends on shares of Common Stock unless the holders of the Preferred A, the Preferred B, and the Preferred CF then outstanding shall first receive a dividend on each outstanding share of Preferred A, Preferred B, and Preferred CF Stock in accordance with the Certificate of Incorporation.

**ii. Liquidation**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Series A Preferred Stock, Series CF Preferred Stock or Common Stock (or any other class or series of capital stock of the Corporation) by reason of their ownership thereof, an amount per share equal to 1.0x times the applicable Series B Original Issue Price, plus any dividends declared but unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the "Series B Liquidation Preference Amount"). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled, the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and after payment to the holders of the Series B Preferred Stock pursuant to the Section above, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event (as defined below), out of the consideration payable to stockholders in such Deemed Liquidation Event or the Available Proceeds (as defined below), before any payment shall be made to the holders of Series CF Preferred Stock or Common Stock (or any other class or series of capital stock of the Corporation) by reason of their ownership thereof, an amount per share equal to 1.0x times the Series A Original Issue Price, plus any dividends declared but unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the "Series A Liquidation Preference Amount"). The "applicable Liquidation Preference Amount" shall refer to the Series B Liquidation Preference Amount with respect to the Series B Preferred Stock, and the Series A Liquidation Preference Amount with respect to the Series A Preferred Stock. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under this Section, and after payment to the holders of Series B Preferred Stock pursuant to the Section above, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and after payment to the holders of the Series B Preferred Stock (as defined above) and payment to the holders of Series A Preferred Stock (as defined above), the holders of shares of Series CF Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event (as defined below), out of the consideration payable to stockholders in such Deemed Liquidation Event or the Available Proceeds (as defined below), before any payment shall be made to the holders of Common Stock (or any other class or series of capital stock of the Corporation) by reason of their ownership thereof, an amount per share equal to 1.0x times the Series CF Original Issue Price, plus any dividends declared but unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the "Series CF Liquidation Preference Amount"). The "applicable Liquidation Preference Amount" shall refer to the Series B Liquidation Preference Amount with respect to the Series B Preferred Stock, the Series A Liquidation Preference Amount with respect to the Series A Preferred Stock and the Series CF Liquidation Preference Amount with respect to the Series CF Preferred Stock. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series CF Preferred Stock the full amount to which they shall be entitled and after payment to the holders of Series B Preferred Stock (as defined above) and payment to the holders of Series A Preferred Stock (as defined above), the holders of shares of Series CF Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all preferential amounts required to be paid to the holders of shares of Preferred Stock pursuant to the Sections above, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to the Sections above or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of the shares of Common Stock and Preferred Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all outstanding shares of Preferred Stock as if they had been converted to Common Stock pursuant to the terms of the Fourth Amended and Restated Certificate of Incorporation immediately prior to such liquidation, dissolution or winding up of the Corporation, without any requirement that any such conversion shall have actually

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

occurred.

**iii. Voting**

On any matter presented to the stockholders of the Company for their action or consideration of any meeting of stockholders of the Company, each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company's Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock bases. The parties' shareholder agreement, voting agreement or other agreement governing the voting of shares by shareholders, shall govern the voting by a shareholder. In addition, the Company is required to obtain the written consent or the affirmative voice of the Series A and Series B Preferred Stockholders for specific corporate activities as defined in the protective provisions of the Certificate of Incorporation for the Series A and Series B Preferred Stockholders respectively.

**iv. Conversion**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series A Original Issue Price by the Series A Conversion Price in effect at the time of conversion. The Series A Conversion Price shall initially be equal to \$2.97822754. The initial Series A Conversion Price, and the rate at which shares of Series A Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series B-1 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series B-1 Original Issue Price by the Series B-1 Conversion Price in effect at the time of conversion. The Series B-1 Conversion Price shall initially be equal to \$3.20862013. The initial Series B-1 Conversion Price, and the rate at which shares of Series A Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series B-2 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series B-2 Original Issue Price by the Series B-2 Conversion Price in effect at the time of conversion. The Series B-2 Conversion Price shall initially be equal to \$3.00808137. The initial Series B-2 Conversion Price, and the rate at which shares of Series B-2 Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series B-3 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series B-3 Original Issue Price by the Series B-3 Conversion Price in effect at the time of conversion. The Series B-3 Conversion Price shall initially be equal to \$4.01077517. The initial Series B-3 Conversion Price, and the rate at which shares of Series B-3 Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series CF-1 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series CF-1 Original Issue Price by the Series CF-1 Conversion Price in effect at the time of conversion. The Series CF-1 Conversion Price shall initially be equal to \$4.01077517. The initial Series CF-1 Conversion Price, and the rate at which shares of Series CF-1

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series CF-2 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series CF-2 Original Issue Price by the Series CF-2 Conversion Price in effect at the time of conversion. The Series CF-2 Conversion Price shall initially be equal to \$4.25. The initial Series CF-2 Conversion Price, and the rate at which shares of Series CF-2 Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

Each share of Series CF-3 Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number for fully paid and non-assessable shares of Common Stock as is determined by dividing the Series CF-3 Original Issue Price by the Series CF-3 Conversion Price in effect at the time of conversion. The Series CF-3 Conversion Price shall initially be equal to \$4.699795. The initial Series CF-3 Conversion Price, and the rate at which shares of Series CF-3 Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment.

**v. Redemption**

If requested by the Requisite Holders (as defined in the Certificate of Incorporation) at any time after the seventh anniversary of the Series B Original Issue Date, February 3, 2023, (the "Redemption Request"), and unless prohibited by Delaware law governing distributions to a stockholder, all issues and outstanding shares of Preferred Stock shall be redeemed by the Company at a price equal to the greater of (A) the applicable Original Issue Price per share, plus all declared by unpaid dividends thereon and (B) the fair market value of a single share of Preferred Stock as of the date of the Company's reception of the Redemption Request paid in three annual installments commencing not more than sixty days after receipt by the Company from the Requisite Holders of a Redemption Request.

**c. Series CF Preferred Stock:**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The Company has authorized three tranches of Series CF shares – 650,000 Series CF-1 shares at \$4.01077517 per share, 117,647 Series CF-2 shares at \$4.25 per share, and 1,000,000 Series CF-3 shares at \$4.699795 per share. The Company has offered via WeFunder Portal LLC a Regulation CF crowdfunding offering of up to \$1,949,999 worth of these Series CF-2 and CF-3 shares. The CF-2 shares are “early bird” shares offered at \$4.25 for the first \$449,998.50 in investment. The remainder of the shares offered via the WeFunder Portal are Series CF-3 shares. The deadline to reach the target offering amount is April 30, 2026; this deadline may be extended, however.

## 10. Revenue

Revenues consist of the following:

---

Subscription fees	\$ 1,361,492
Implementation fees	259,101
<b>Total Revenues</b>	<b>\$ 1,620,593</b>

## 11. Stock-based compensation

On March 20, 2018, the Company established the 2018 Equity Incentive Plan, which was later amended on December 28, 2019, again on July 22, 2021, and most recently on April 28, 2025. The number of shares available for grant or option under the plan shall not exceed 4,253,000 shares. The shares granted or optioned under this plan may be either authorized but unissued or reacquired shares. Awards under the plan may consist of (i) options, (ii) stock awards, and (iii) restricted stock.

The 2018 Stock Incentive Plan may grant restricted stock to eligible persons which entitle the participants to receive the shares underlying those awards upon vesting or upon the expiration of a designated time period following the vesting of those awards. Restricted stock may, in the discretion of the plan administrator, vest in one or more installments over the participant's period of service or upon the attainment of specified performance objectives. Outstanding restricted stock shall automatically terminate, and no shares of common stock shall be issued in satisfaction of those awards, if the performance goals or service requirements established for those awards are not attained or satisfied. The plan administrator shall have the discretionary authority to issue vested shares of common stock under one or more outstanding awards of restricted stock as to which the designated performance goals or service requirements have not been attained or satisfied.

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

A summary of the activity under the Company's Stock Option Plan for the year ended December 31, 2025 is as follows:

	Options	Weighted Average Exercise Price \$	Weighted Average Contractual Life (In Years)
Outstanding as of December 31, 2024	1,650,518	0.27	6.23
Granted	198,150	0.45	9.38
Exercised	(31,812)	0.30	5.13
Forfeited	(103,626)	-	-
Outstanding as of December 31, 2025	1,713,230	0.28	5.59
Options exercisable at December 31, 2025	1,421,647	0.26	5.09

The Company has estimated the fair value of all stock option awards as of the date of grant by applying the Black- Scholes option-pricing model. The weighted average assumptions used in determining the fair value of options granted during the years ended December 31, 2025 are as follows:

Risk-free interest rate	3.75%
Expected life	5 years
Expected volatility	65%
Expected dividend yield	0%

For the year ended December 31, 2025, the Company recognized share-based compensation expense of \$45,623.

**12. Going concern**

See independent auditor's report. The accompanying notes are an integral part of these financial statements.

**Koios Medical, Inc.**  
Notes to the Financial Statements  
For the year ended December 31, 2025

The accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has generated minimal revenues from operations since inception but does expect to increase revenues substantially in the foreseeable future. For the year ended December 31, 2025, the Company incurred a net loss in the amount of \$2,687,228 and has an accumulated deficit of \$41,595,216 at December 31, 2025. The Company has financed its working capital requirements to date through the sale of common stock, preferred stock, and convertible promissory notes. The Company is raising additional funds through the sale of common stock and preferred stock under Regulation D and through a Crowdfunding round under Regulation CF, although there are no assurances the Company will be successful. Without this capital injection (or an equivalent alternative), the Company may face significant challenges in maintaining operations or achieving its growth targets.

These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result should the Company be unable to continue as a going concern.

**13. Subsequent events**

In 2026 through April 8, the Company has raised over \$1.1 million and closed on over \$900,000 via WeFunder Portal LLC through its Regulation CF crowdfunding platform.

The Company has also settled for \$34,000 a dispute with a contractor that claimed an outstanding balance owed of \$42,986 with payments to be made monthly during the year.

Management evaluated all activity of the Company through April 9, 2026 (the issuance date of the financial statements) and concluded that no other subsequent events have occurred that would require recognition in the financial statements or disclosure in the related notes to the financial statements.

See independent auditor's report. The accompanying notes are an integral part of these financial statements.